Balaji Amines Ltd

Net profit of Balaji Amines declined 41.11% to Rs 40.06 crore in the quarter ended March 2025 as against Rs 68.03 crore during the previous quarter ended March 2024. Sales declined 14.79% to Rs 352.73 crore in the quarter ended March 2025 as against Rs 413.94 crore during the previous quarter ended March 2024. For the full year,net profit declined 23.10% to Rs 157.52 crore in the year ended March 2025 as against Rs 204.85 crore during the previous year ended March 2024. Sales declined 14.89% to Rs 1397.08 crore in the year ended March 2025 as against Rs 1641.51 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales352.73413.94 -15 1397.081641.51 -15 OPM %16.9123.60 -16.6219.72 - PBDT66.84105.16 -36 261.66346.93 -25 PBT53.9492.91 -42 213.22301.56 -29 NP40.0668.03 -41 157.52204.85 -23 Powered by Capital Market - Live

Profit before tax (PBT) stood at Rs 53.93 crore in Q4 FY25, down 41.94% year-on-year but up 31.89% quarter-on-quarter. EBITDA stood at Rs 68 crore in Q4 FY25, down 35.84% year-on-year but up 25.92% quarter-on-quarter. EBITDA margin declined to 19% in Q4 FY25, compared to 25% in Q4 FY24 and 17% in Q3 FY25. Total expenses fell 6.96% to Rs 306.82 crore in Q4 FY25 over Q4 FY24. During the quarter, the cost of materials consumed stood at Rs 180.64 crore (down 25.84% YoY), while employee benefits expense was at Rs 22.88 crore (down 6.72% YoY). The company's revenue from the amines amines derivatives volumes stood at 8,389 MT, and specialty chemicals volumes stood at 7,342 MT. On a full year basis, the company's consolidated net profit tanked 31.73% to Rs 158.59 crore on 14.89% decline in revenue from operations to Rs 1,397.08 crore in FY25 over FY24. On the performance, D. Ram Reddy, Managing Director, commented, 'During Q4 FY25, our business performance showed improvement compared to the rest of the financial year, supported by favorable global macroeconomic conditions. As volume uptake gradually increases, we expect EBITDA and PAT margins to improve in line with broader industry recovery trends. However, geopolitical tensions and tariff-related challenges across global markets may continue to impact growth across several sectors in which we operate. These factors have weighed on domestic demand, but we anticipate that better utilization of expanded capacities will support margin recovery in the coming quarters. Pharmaceutical sector demand remained steady, contributing to base volumes, while the agrochemical segment exhibited volatility during the quarter. We continue to make progress on our strategic capex initiatives, including Electronic Grade DMC, Propylene Glycol Pharma Grade, and Dimethyl Ether projects, which are moving forward as planned. On the sustainability front, we are pleased to announce that our 6 MW AC Solar Power Plant was commissioned on 2 nd April, 2025. The plant is being brought online in a phased manner under Grid Connectivity, and the power generated will be utilized for captive consumption. Looking ahead, we remain focused on enhancing operational efficiencies, managing input costs and expanding our product portfolio to deliver sustained value to all stakeholders.' Meanwhile, Balaji Amines, through its subsidiary Balaji Speciality Chemicals, is investing approximately Rs 750 crore in a new expansion project. The greenfield project will manufacture a range of products, including Hydrogen Cyanide (HCN), Sodium Cyanide (NaCN) 30% solution and 100% solid, EDTA/EDTA-2Na, Benzyl Cyanide (BnCN), Phenylacetic Acid (PAA), and Triethyl Orthoformate (TEOF)/Trimethyl Orthoformate (TMOF). This project is currently under execution and is expected to be commissioned by the end of FY 2025-26. Additionally, a brownfield project for manufacturing EDA-based products at Unit-I is progressing as planned and is expected to be commissioned in FY 2026-27. Further, the company has recommended a final dividend of Rs 11 per equity share, which translates to 550% on a face value of Rs 2 per share. The dividend will be payable subject to approval by the shareholders at the 37th Annual General Meeting of the company. The board has approved the re-appointment of A. Prathap Reddy as executive chairman of the company for a period of five years, effective from 1 April 2026, subject to shareholder approval. Additionally, the board has approved the re-appointment of D. Ram Reddy as managing director for a further term of five years, also effective from 1 April 2026, pending shareholder approval. Balaji Amines is a leading manufacturer of aliphatic amines in India. Broadly, the company is specialized in manufacturing methyl amines, ethyl amines, derivatives of specialty chemicals, and natural products, and its business is broadly classified into three segments: amines, specialty chemicals, and derivatives. Powered by Capital Market - Live

Balaji Amines announced that the Board of Directors of the Company at its meeting held on 28 May 2025, inter alia, have recommended the final dividend of Rs 11 per equity Share (i.e. 550%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Balaji Amines has revised the meeting of the Board of Directors which was scheduled to be held on 26 May 2025. The meeting will now be held on 28 May 2025.Powered by Capital Market - Live

Balaji Amines will hold a meeting of the Board of Directors of the Company on 26 May 2025.Powered by Capital Market - Live

Profit before tax slipped 41.81% year on year to Rs 40.89 crore in the quarter ended 31 December 2024. EBITDA for Q3 FY25 stood at Rs 54 crore, down 34.94%, compared to Rs 83 crore in Q3 FY24. EBITDA margin for Q3 FY25 was reduced to 17% in Q3 FY25 as against 21% reported in the same period a year ago. Total expense declined 13.02% YoY to Rs 279.70 crore during the quarter. Cost of raw material consumed stood at Rs 168.50 crore (down 16.29% YoY), while employee benefits expenses were at Rs 18.53 crore (down 9.83% YoY) in Q3 FY25. The company's revenue from the amines amines derivatives volumes stood at 8,809 MT, and specialty chemicals volumes stood at 7,773 MT. On a standalone basis, the company's net profit declined 14.1% to Rs 35.69 crore in Q3 FY25 as against Rs 41.55 crore posted in Q3 FY24. Revenue from operations was at Rs 299.23 crore in Q3 FY25, down 2.79% YoY. Meanwhile, the company has installed rooftop solar plants at various locations, and the Maharashtra State Electricity Distribution Company (MSEDCL) has approved these installations. The capacities of these solar units for captive consumption are 2.655 MW, and the expected unit generated is approximately 12 lakh units. D. Ram Reddy, MD, Balaji Amines, said, 'During Q3 FY25, our financial and business performance remained stable despite the challenges posed by global macroeconomic conditions. However, as volume uptake gradually increases, EBITDA and PAT margins are expected to improve in line with industry recovery. The resurgence in domestic demand, along with positive trends in international markets, is driving this momentum. Additionally, the utilization of expanded capacities will contribute to margin enhancement as some of our products progress through the final approval stages with end-user industries. This progress is further supported by our ongoing investments in key projects, reinforcing our commitment to operational excellence. Electronic Grade DMC, Propylene Glycol Pharma Grade, and Dimethyl Ether projects are progressing well, aligning with our strategic growth objectives. These initiatives are designed to strengthen our market presence, enhance product offerings, and meet the evolving needs of our customers. Looking ahead, we maintain a positive outlook for long-term opportunities, anticipating growth and increased prospects during the fiscal year 2025-26. Our focus on inherent strengths and competencies positions us as a leading force in amines and specialty chemicals, guiding us through market complexities towards greater excellence.' Balaji Amines is a leading manufacturer of aliphatic amines in India. Broadly, the company is specialized in manufacturing methyl amines, ethyl amines, derivatives of specialty chemicals, and natural products, and its business is broadly classified into three segments: amines, specialty chemicals, and derivatives.Powered by Capital Market - Live

Net profit of Balaji Amines declined 32.77% to Rs 33.19 crore in the quarter ended December 2024 as against Rs 49.37 crore during the previous quarter ended December 2023. Sales declined 18.42% to Rs 312.73 crore in the quarter ended December 2024 as against Rs 383.36 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales312.73383.36 -18 OPM %14.6219.36 - PBDT52.7781.12 -35 PBT40.8970.27 -42 NP33.1949.37 -33 Powered by Capital Market - Live

Balaji Amines will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live

Revenue from operations declined 8.85% year on year (YoY) to Rs 346.88 crore in the quarter ended 30 September 2024. Profit before tax stood at Rs 56.81 crore in September 2024 quarter, registering a growth of 18.33% on YoY basis. Sequentially, the company's net profit and revenue from operations in second quarter of FY25 declined 5.34% and 9.84%, respectively. EBITDA during the quarter stood at Rs 70 crore, down 5.41% as compared to Rs 74 crore in Q1 of FY25. EBITDA margin for Q2FY25 improved to 20% in Q2 FY25 as against 19% reported in the same period a year ago. Total expenses declined 11.8% YoY to Rs 299.26 crore during the quarter. Cost of raw material consumed stood at Rs 221.88 crore (up 16% YoY) while other expenses were at Rs 78.92 crore (down 7.31% YoY) in Q2 FY25. The company's revenue from amines amines derivatives volumes stood at 8,685 MT and specialty chemicals volumes stood at 10,046 MT. Looking ahead, Balaji Amines is proposing to set up a plant for manufacture of N-(N-Butyl) Thiophosphoric Triamide (NBPT) with a capacity of 2500 TPA which will be taken up next Financial Year. Additionally, the company aims to expand its ACN production capacity by setting up a new plant with a 60 MT/day capacity at Unit-III in MIDC, Chincholi. The discussion for transfer of the latest technology (reducing the cost of production) is under final stage and the company may sign the agreement by the end of November 2024. New equipment as per the latest technology will be integrated with the existing ACN plant at Unit-III. In a separate development, Balaji Speciality Chemicals, a subsidiary of Balaji Amines, has planned a major expansion with an investment of approximately Rs 750 c rore. This project will focus on a range of products, including Hydrogen Cyanide (HCN), Sodium Cyanide (NaCN) in both 30% solution and 100% solid forms, EDTA, EDTA-2Na, Benzyl Cyanide (BnCN), Phenylacetic Acid (PAA), and Tri Ethyl Ortho Formate (TEOF)/Tri Methyl Ortho Formate (TMOF). D. Ram Reddy, managing director, Balaji Amines, said, 'In the Q2 quarter, we reported a revenue of Rs 356 crore, achieving an EBITDA margin of 20%. This marks a 110-basis-point improvement over last quarter, reflecting our focus on higher margin products amid a challenging industry environment. While the broader market experienced pressure in Q2, both the API and agrochemical looks promising over a long term, and we are well-positioned to seize these future opportunities. With our expanded capacities and a sharpened focus on operational efficiency, we are confident in our ability to drive sustainable growth in the coming quarters. Our recent developments demonstrate significant progress in expanding our production capacity. With the successful commencement of Methylamines production at Unit-IV, our total annual installed capacity has increased from 48,000 MT to 88,000 MT across all three units. Additionally, Unit-I and Unit-III have achieved BIS Certification for 'Morpholine,' strengthening our quality standards and making us the only BIS-certified Morpholine manufacturer in India. Projects in Electronic Grade DMC, Propylene Glycol Pharma Grade, and Dimethyl Ether are also advancing well, reflecting our commitment to operational excellence. As we look forward, our strong foundation in core capabilities positions us well to navigate industry dynamics and capture growth opportunities.' Balaji Amines is a leading manufacturer of aliphatic amines in India. Broadly, the company is specialized in manufacturing methyl amines, ethyl amines, derivatives of specialty chemicals and natural product and its business is broadly classified into three segments - amines, specialty chemicals and derivatives. Shares of Balaji Amines declined 1.92% to Rs 1,996.15 on the BSE. Powered by Capital Market - Live

Net profit of Balaji Amines rose 18.06% to Rs 40.98 crore in the quarter ended September 2024 as against Rs 34.71 crore during the previous quarter ended September 2023. Sales declined 8.85% to Rs 346.88 crore in the quarter ended September 2024 as against Rs 380.54 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales346.88380.54 -9 OPM %17.4914.14 - PBDT68.8158.79 17 PBT56.8148.01 18 NP40.9834.71 18 Powered by Capital Market - Live